

H. Al-Salami, et al. [2008] Med. Hypotheses Res. 4: 93–101.

## Probiotic Treatment Proceeded by a Single Dose of Bile Acid and Gliclazide Exert the Most Hypoglycemic Effect in Type 1 Diabetic Rats

Hani Al-Salami\*, Grant Butt, Ian Tucker, Ranko Skrbic, Svetlana Golocorbin-Kon and Momir Mikov

New Zealand's National School of Pharmacy (H.A-S., I.T., M.M), Department of Physiology (G.B.), and Department of Pharmacology (R.S., S.G.K.), University of Otago, Dunedin 9054, New Zealand

**Abstract.** Probiotics have beneficial effects in treating diabetes and may form a useful adjunct to established hypoglycemic drugs. Here we report the effect of pre-treatment with probiotics followed by the oral administration of gliclazide + MKC (a semisynthetic bile acid), on blood glucose levels (BGL) and gliclazide pharmacokinetics in a rat model of type 1 diabetes (T1D). Male Wister rats were randomly divided into 8 groups (N = 10), 4 of which were made diabetic by i.v. injection of alloxan. Groups 1–4 were administered a single dose of gliclazide + MKC (20 and 4 mg/kg, respectively) by oral gavage while groups 5–8 by i.v. Group 1 was healthy while group 2 was diabetic. Groups 3 (healthy) and 4 (diabetic) were gavaged with probiotic mixture for three days and 12 h after the last ingestion of probiotics, a baseline blood sample was taken from all 8 groups of rats and gliclazide + MKC was administered. Blood samples collected prior to gliclazide revealed probiotic treatment significantly reduced BGL in diabetic rats which were further reduced after gliclazide + MKC oral dose. Moreover, in probiotic treated healthy rats, gliclazide bioavailability was the lowest. In contrast, in probiotic treated diabetic rats, gliclazide bioavailability was higher than untreated diabetic rats. Probiotic treatment lowers BGL and increases gliclazide absorption in this model of T1D. Our results suggest that a multidrug approach to treating diabetes can prove useful with MKC, gliclazide and probiotics being potential adjuvant treatments.

*Correspondence:* Dr. Hani Al-Salami, New Zealand's National School of Pharmacy, University of Otago, Level 6, Adams Building, 18 Frederick Street, PO Box 913, Dunedin 9054, New Zealand. Tel: 64 3 479 5285. Fax: 64 3 479 7034. E-mail: Hhani.al-salami@stonebow.otago.ac.nz

*Abbreviations used:* T1D, type 1 diabetes; BGL, blood glucose level.

Received on 04-10-2008; accepted on 05-18-2008.

## 1. Introduction

Type 1 diabetes (T1D) is a common disease that predominantly develops during childhood. The clinical presentation of T1D is marked hyperglycaemia [1] which result from the destruction of the pancreatic  $\beta$  cells [2,3]. Although a number of hypotheses explaining the pathogenesis of T1D [3] have been proposed, the most accepted explanation is that T1D is a chronic inflammatory disease which is triggered in genetically susceptible individuals by the dysfunction of the gut-mediated oral tolerance to ingested proteins and the consequent change in the bile acids metabolism [4-6].

MKC is a semisynthetic analogue of cholic acid [7] and has a hypoglycemic effect when given orally to type 1 diabetic rats [8]. Furthermore, a stronger hypoglycemic effect was noticed in diabetic rats following the oral administration of the combined mixture of MKC and the antidiabetic drug gliclazide [9]. Gliclazide is a second generation sulphonylurea used to treat type 2 diabetes [10,11]. Its primary mode of action is to induce insulin secretion by pancreatic  $\beta$ -cells [12,13]. Gliclazide has also other beneficial effects such as stimulating the synthesis of glucose transporters [14], reducing hepatic glucose production, improving glucose turnover, and improving glucose uptake by muscles [15,16]. Accordingly, its application in type one diabetes can prove useful especially when combined with other hypoglycemic agents [9,17]. In an in vivo study in our laboratory, we have shown that probiotic treatment for three days resulted in a hypoglycemic effect on alloxan-induced diabetic rats [18].

Probiotics are dietary supplements that contain live bacteria, which when administered in adequate amounts, confer a health benefit on the host (19). In order to achieve a synergistic effect, combinations of different bacterial strains should be used in probiotics [20,21] with *Lactobacillus* and *Bifidobacteria* being a common choice [21]. In one in vivo study, probiotics induced the production of IL-10 which has been linked with the prevention of T1D [22]. Moreover, in studies using probiotics, researchers were able to show clinical improvements of

patients with T1D as well as certain degree of prevention if administered early [5,23-27].

With probiotics and bile acids presenting a great potential for T1D treatment, their integration with other antidiabetic drugs, in a multi-drug therapy should be investigated thoroughly. The aim of this in vivo study was to investigate the influence of MKC as a hypoglycemic agent, on the bioavailability of the antidiabetic drug gliclazide in diabetic rats treated with probiotics.

## 2. Materials and Methods

### 2.1. Materials

Gliclazide (99.9%) and alloxan (98%) were purchased from Sigma Chemical Co, St Louis, MO, USA. Ultra water-soluble transmission gel (hypoallergenic) was purchased from Medtel Pty. Ltd. NSW, Australia. MKC was synthesized and purified in the Department of Pharmacology, University of Novi Sad, Serbia, by the method of Miljkovic et al. [28]. Freeze-dried cultures of *Lactobacillus acidophilus*, *Bifidobacterium lactis*, and *Lactobacillus rhamnosus* were kindly provided by Professor John Tagg (Department of Microbiology, University of Otago, New Zealand) and Dr. Chris Chilcott (BLIS Technologies, Dunedin, New Zealand). The cultures were originally Howaru™ strains obtained from Danisco NZ Ltd, Auckland, New Zealand. All other chemicals and solvents were of HPLC grade.

### 2.2. Drugs preparations

A gliclazide suspension (20 mg/mL) was prepared by adding gliclazide powder to 10% Ultra water-soluble gel and while a MKC solution (5 mg/mL) was prepared by adding MKC powder to 2% NaHCO<sub>3</sub> solution. Drug preparations were mixed thoroughly at 37°C for 6 h, stored in the refrigerator, and were used within 48 h of preparation. A probiotic suspension (75 mg/kg, 1011 cells/g) containing equal amounts of *Lactobacillus acidophilus*, *Bifidobacterium lactis*, and *Lactobacillus rhamnosus*, was prepared by mixing the probiotic powders with HPLC water and was used immediately after preparation.

### 2.3. Animals

Male Wister rats (age 2–3 months, weight  $350 \pm 50$  g) were maintained in an experimental animal facility and given standard diet and water ad libitum. Temperature and light were controlled to mimic the natural habitat. Eighty rats were randomly divided into 8 groups (N = 10), four of which were made diabetic by injecting freshly prepared alloxan solution (30 mg/mL) intravenously into the tail vein at a dose of 30 mg/kg [17,29,30]. Rats with blood glucose > 20 mmol/L and serum insulin < 0.04  $\mu$ g/L 2 to 3 days after alloxan injection were considered diabetic [17,31–33]. Diabetic rats showed signs of polydipsia, polyuria, weight loss and asthenia [29,34]. The study was approved by the Otago University Animal Ethics Committee.

### 2.4. Experimental protocol

Groups 1–4 were administered a single dose of gliclazide + MKC (20 and 4 mg/kg, respectively) by the oral route (gavage) while groups 5–8 were administered drug(s) via the intravenous (i.v) route (tail vein). Group 1 was healthy while group 2 was made diabetic as described above. Groups 3 (healthy) and 4 (diabetic) were gavaged with probiotic mixture twice daily for three days then 12 h after the last ingestion of probiotics, a baseline blood sample was taken from all 8 groups of rats and a single dose of gliclazide + MKC was administered either via the oral route (groups 1–4) or i.v. route (groups 5–8). Blood samples were then collected from the tail vein at 5, 10, 20, 40, 60, 80, 120, 150, 180, 240, 360 and 600 min after the dose. Insulin concentration in blood was measured using Merckodia Ultra Sensitive Rat Insulin Elisa (Sweden). Blood glucose was measured using an ACCU-CHEK Glucose Advantage Meter (Roche). Serum was separated by centrifugation at 15000 rpm for 5 min and kept at  $-20^{\circ}\text{C}$  pending analysis for gliclazide within 2 days of collection.

### 2.5. HPLC

Gliclazide concentration in serum was measured by HPLC using a method based on the

literature [35,36]. Acetonitrile was added to serum samples in a 2:1 ratio and, after vortexing for 10 s and centrifuging (15000 rpm) for 15 min, the supernatant (20  $\mu$ L) was injected into the HPLC system. This consisted of a Shimadzu, SIL-10AD VP autoinjector, a  $\text{C}_{18}$  guard column ( $4 \times 2.0$  mm, Phenomenex), a  $\text{C}_{18}$  analytical column ( $100 \times 2.0$  mm Luna 5  $\mu$ m, Phenomenex) and a Shimadzu, UV-V15 detector set at 229 nm. The mobile phase was acetonitrile 49% and water 51%, pH 2.7 (adjusted using orthophosphoric acid) at a flow rate of 0.4 mL/min. Under these conditions, the retention time for gliclazide was 2.9 min. A gliclazide standard curve was constructed in serum in the range 0.5–100  $\mu$ g/mL. The assay was linear with a within-day coefficient of variation ranging from 1.2% at 100  $\mu$ g/mL to 2.9% at 0.5  $\mu$ g/mL. The limit of detection was 0.5  $\mu$ g/mL and the limit of quantitation was 0.8  $\mu$ g/mL. The recovery of gliclazide from serum was  $89 \pm 4\%$ .

### 2.6. Pharmacokinetic analysis

Pharmacokinetic (PK) and pharmacodynamic (PD) parameters were calculated from the serum concentration–time data using the WinNonLin, version 4.1 (SCI software, Pharsight Corporation, Gary, NC, USA) while statistical comparisons were made using Minitab (Minitab, Version 14 ; Minitab Inc, Pennsylvania, USA).

Gliclazide serum concentration–time data were analyzed using a noncompartmental model. Maximum concentration ( $C_{\text{max}}$ ) and the time to maximum concentration ( $t_{\text{max}}$ ) were derived directly from the data. Total area under the plasma concentration–time curve ( $\text{AUC}_{0-t}$ ) was calculated by the trapezoidal method and extrapolated to infinity ( $\text{AUC}_{0-\infty}$ ). Half-life ( $t_{1/2}$ ) was calculated from the elimination rate constant  $k_e$  (determined using the last three points). Bioavailability (F) was calculated as  $\text{AUC}_{0-t}$  (oral)/ $\text{AUC}_{0-t}$  (i.v.). The mean residence time (MRT) was calculated from the  $\text{AUC}_{0-\infty}$ . Total body clearance (Cl) was calculated as Dose/ $\text{AUC}_{0-t}$ . The volume of distribution area ( $V_{\text{darea}}$ ) was calculated using the equation [37]:

$$V_{\text{darea}} = \text{dose} / (\text{AUC}_{0-\infty} \times \beta).$$




Figure 2. Blood glucose concentration-time curves after i.v. administration of gliclazide + MKC (20 and 4 mg/kg, respectively) to healthy and diabetic rats with and without probiotic pre-treatment.

2.7. Pharmacodynamic and PK/PD analysis

The effect of gliclazide + MKC on blood glucose concentration was calculated according to the sigmoid E<sub>max</sub> model. The PK/PD equation was expressed as follows:  $E = E_0 - \{(E_{max} \times C_e) / (EC_{50} + C_e)\}$  in which E is the hypoglycemic effect of the drug, E<sub>0</sub> is the baseline blood glucose level before drug administration, EC<sub>50</sub> is the concentration of drug producing 50% of the maximum effect on blood glucose, E<sub>max</sub> is the maximum

effect on blood glucose level resulting from drug administration, and C<sub>e</sub> is the drug concentration in serum which produces the hypoglycemic effect (E). For C<sub>e</sub>, E<sub>max</sub>, E<sub>0</sub> and EC<sub>50</sub> measurements, PD model 108 was used [Inhibitory Effect Sigmoid E maximum, with C<sub>e</sub> = 0 at E<sub>0</sub> and C<sub>e</sub> = ∞ at E<sub>max</sub>].

2.8. Statistical analysis

Values are expressed as mean ± SD. Statistical




Figure 1. Blood glucose concentration-time curves after oral administration of gliclazide + MKC (20 and 4 mg/kg, respectively) to healthy and diabetic rats with and without probiotic pre-treatment.




Figure 3. Gliclazide serum concentration after i.v. administration of gliclazide + MKC (20 and 4 mg/kg, respectively) to healthy and diabetic rats with and without probiotic pre-treatment.

comparisons between healthy and diabetic rats after oral and i.v. administration were carried out using the Wilcoxon matched pairs test at 95% CI while statistical comparisons between probiotic treated and untreated rats after oral and i.v. administration were carried out using the General Linear Model (GLM) to perform analysis of variance (ANOVA) with probiotic treatment as the discrete (fixed) factor at an  $\alpha$  level of 0.05. Statistical significance was set at  $P < 0.05$ .

### 3. Results

Treatment with probiotics for three days had no effect on blood glucose levels in healthy rats but significantly reduced the elevated blood glucose levels in diabetic rats from  $23.8 \pm 3.0$  mmol/L to  $12.6 \pm 2.0$  mmol/L ( $P < 0.01$ ). Furthermore, there were no significant changes in blood glucose in any group of rats after the i.v. (Fig. 1) but, after oral administration of MKC + gliclazide to untreated diabetic rats, the elevated




Figure 4. Gliclazide serum concentration after oral administration of gliclazide + MKC (20 and 4 mg/kg, respectively) to healthy and diabetic rats with and without probiotic pre-treatment.

**TABLE 2. Pharmacokinetic parameters of gliclazide after i.v. administration of gliclazide + MKC (20 and 4 mg/kg, respectively) to healthy and diabetic rats with and without probiotic pre-treatment. Data are means  $\pm$  SD (N = 10).**

Pharmacokinetic parameters	i.v. healthy	i.v. diabetic	Sig.	i.v. healthy-probiotics	i.v. diabetic-probiotics	Sig.
MRT (min)	486 $\pm$ 124	470 $\pm$ 115	NS	451 $\pm$ 112	480 $\pm$ 183	NS
V <sub>d</sub> area (mL/kg)	127 $\pm$ 34	119 $\pm$ 44	NS	156 $\pm$ 40	146 $\pm$ 34	NS
T <sub>1/2</sub> (min)	102 $\pm$ 39	100 $\pm$ 26	NS	113 $\pm$ 58	126 $\pm$ 52	NS
C <sub>max</sub> ( $\mu$ g/mL)	-	-	-	-	-	-
t <sub>max</sub> (min)	-	-	-	-	-	-
AUC <sub>0-t</sub> (min $\times$ $\mu$ g/mL)	(2.01 $\pm$ 0.57) $\times$ 10 <sup>4</sup>	(1.46 $\pm$ 0.66) $\times$ 10 <sup>4</sup>	NS	(1.91 $\pm$ 0.24) $\times$ 10 <sup>4</sup>	(1.98 $\pm$ 0.35) $\times$ 10 <sup>4</sup>	NS
AUC <sub>0-∞</sub> (min $\times$ $\mu$ g/mL)	(2.20 $\pm$ 0.74) $\times$ 10 <sup>4</sup>	(1.58 $\pm$ 0.58) $\times$ 10 <sup>4</sup>	NS	(1.99 $\pm$ 0.50) $\times$ 10 <sup>4</sup>	(2.08 $\pm$ 0.51) $\times$ 10 <sup>4</sup>	NS
Cl ( $\mu$ g/mL/min)	0.019 $\pm$ 0.008	0.021 $\pm$ 0.013	NS	0.026 $\pm$ 0.010	0.021 $\pm$ 0.011	NS

Sig: significance level

NS: not significant

**TABLE 2. Pharmacokinetic parameters of gliclazide after i.v. and oral administration of gliclazide + MKC (20 and 4 mg/kg, respectively) to healthy and diabetic rats with and without probiotic pre-treatment. Data are means  $\pm$  SD (N = 10).**

Pharmacokinetic parameters	Oral healthy	Oral diabetic	Sig.	Oral healthy-probiotics	Oral diabetic-probiotics	Sig.
MRT (min)	484 $\pm$ 247	462 $\pm$ 197	NS	466 $\pm$ 139	462 $\pm$ 197	NS
V <sub>d</sub> area (mL/kg)	143 $\pm$ 30	138 $\pm$ 44	NS	138 $\pm$ 29	153 $\pm$ 65	NS
T <sub>1/2</sub> (min)	123 $\pm$ 67	161 $\pm$ 42	NS	141 $\pm$ 35	156 $\pm$ 93	NS
C <sub>max</sub> ( $\mu$ g/mL)	64 $\pm$ 10	30 $\pm$ 8	S	28 $\pm$ 7	44 $\pm$ 8	S
t <sub>max</sub> (min)	112 $\pm$ 39	94 $\pm$ 47	NS	84 $\pm$ 19	89 $\pm$ 28	NS
AUC <sub>0-t</sub> (min $\times$ $\mu$ g/mL)	(1.58 $\pm$ 0.32) $\times$ 10 <sup>4</sup>	(0.60 $\pm$ 0.23) $\times$ 10 <sup>4</sup>	S	(0.53 $\pm$ 0.09) $\times$ 10 <sup>4</sup>	(1.10 $\pm$ 0.23) $\times$ 10 <sup>4</sup>	S
AUC <sub>0-∞</sub> (min $\times$ $\mu$ g/mL)	(1.73 $\pm$ 0.7) $\times$ 10 <sup>4</sup>	(0.63 $\pm$ 0.24) $\times$ 10 <sup>4</sup>	S	(0.55 $\pm$ 0.12) $\times$ 10 <sup>4</sup>	(1.21 $\pm$ 0.51) $\times$ 10 <sup>4</sup>	S
Cl ( $\mu$ g/mL/min)	0.038 $\pm$ 0.007	0.041 $\pm$ 0.010	NS	0.050 $\pm$ 0.026	0.048 $\pm$ 0.018	NS
Bioavailability %	79.4 $\pm$ 4.7	40.0 $\pm$ 4.3	S	27.9 $\pm$ 4.9	55.6 $\pm$ 5.8	S

S: significant

NS: not significant

blood glucose level was significantly reduced (Fig. 2). Oral administration of MKC + gliclazide to diabetic rats treated with probiotics also resulted in a small but significant hypoglycemic effect ( $E_{max} = 9.34 \pm 2.0$ ) ( $P < 0.01$ ). Interestingly, diabetic rats pre-treated with probiotics showed reduction in weight loss, urine production and

water consumption, and improvement in behaviour (curious, active) and survival rate when compared with untreated diabetic rats.

Gliclazide pharmacokinetic parameters were not affected by the concomitant administration of MKC by the i.v. route in either healthy or diabetic rats with and without

probiotic pre-treatment (Fig. 3, Table 1). However, after oral administration,  $C_{max}$ , AUC and F values of gliclazide were much lower in untreated diabetic rats than in untreated healthy rats. In contrast,  $C_{max}$ , AUC and F values of gliclazide were much higher in probiotic treated diabetic rats than in probiotic treated healthy rats, and approached levels in untreated healthy rats (Fig. 4, Table 2). These values were similar with those of treated diabetic rats given gliclazide alone [38] suggesting that gliclazide systemic absorption in probiotic treated diabetic animals does not change as a result of the concomitant administration of MKC. Interestingly,  $C_{max}$ , AUC and F values of oral gliclazide in untreated healthy rats were higher when given with MKC. Moreover, in untreated healthy rats, the bioavailability of gliclazide increased from  $54.4 \pm 5.4$  when given alone [9] to  $79.4 \pm 4.7$  when given with MKC, while, in probiotic treated diabetic rats, gliclazide bioavailability was unchanged,  $55.6 \pm 5.8$  (Table 2), *vs*  $56.2 \pm 6.4$  [9], suggesting a different effect of MKC on gliclazide pharmacokinetics in diabetic animals.

#### 4. Discussion

In previous *in vivo* studies, we have shown that MKC had a hypoglycemic effect when administered to alloxan-induced diabetic rats [8], and the combination of gliclazide and MKC had a synergistic hypoglycemic effect on diabetic rats which was greater than MKC alone [8,9]. Furthermore, in another *in vivo* study, we have shown that probiotic treatment had a hypoglycemic effect in alloxan-induced diabetic rats when given at the early stages of the disease [38]. Accordingly, in this *in vivo* study, we investigate the influence of probiotic treatment followed by the oral administration of gliclazide + MKC, on blood glucose levels while monitoring gliclazide pharmacokinetic parameters in healthy and diabetic rats.

At the start of experiments, all baseline (E0) values for untreated and probiotic treated healthy and diabetic rats were comparable. Intravenous administration of gliclazide + MKC to healthy and diabetic rats with and without

probiotic pre-treatment produced little hypoglycemic effect. However, oral administration of gliclazide + MKC to diabetic rats produced a significant hypoglycemic effect suggesting the hypoglycemic effect of gliclazide + MKC in probiotic treated diabetic rats is due to the activation of MKC in the gut. The orally administered combination of gliclazide and MKC produced a greater hypoglycemic effect in diabetic rats than MKC alone. This synergistic effect of gliclazide after oral application could be due to gliclazide enhancing the production and/or the absorption of MKC active metabolites in the gut. The oral administration of MKC + gliclazide to probiotic treated diabetic rats also produced a significant reduction in blood glucose levels from  $12.6 \pm 2.0$  mmol/L to  $9.3 \pm 2.0$  mmol/L ( $P < 0.01$ ). This may suggest probiotic treatment enhances the activation of MKC metabolism in a similar way to the reported bacterial activation of some primary bile acids [39,40]. On the other hand, in healthy rats treated with probiotics, neither gliclazide, MKC or MKC + gliclazide had an effect on blood glucose levels suggesting the presence of efficient compensatory mechanisms including glycogenolysis, glycogenesis, and gluconeogenesis. Overall, pre-treatment with probiotics then subsequent oral administration of MKC + gliclazide to T1D rats resulted in optimum control over hyperglycemia as well as improved signs and symptoms in those diabetic animals.

Probiotic pre-treatment reduces the bioavailability of gliclazide after oral dose of gliclazide + MKC in healthy rats while the same probiotic pre-treatment increases the bioavailability in diabetic rats. The decrease in gliclazide bioavailability in healthy rats caused by probiotic treatment can be explained in the following way. Firstly, probiotics may activate efflux drug transporters that influence gliclazide absorption. Secondly, probiotics cause the formation of a 'thicker' layer of adherent mucous in the GIT [38,41], or improve the tightness of the intestinal barrier [42]. This newly formed 'bacterial' layer reduces the ability of gliclazide to reach the mucosal membrane of the enterocytes resulting in less drug being absorbed. Lastly, probiotics may bind free MKC

in a similar way to that reported between cholic acid and Lactobacilli [43] and consequently restricting gliclazide + MKC access to site of absorption in the gut. On the other hand, the increase in gliclazide bioavailability in diabetic rats caused by probiotic treatment can be explained by the following. Firstly, probiotic treatment can restore the activity of drug transporters responsible for MKC uptake. These drug transporters we have shown in previous *ex vivo* studies [18,44,45] to be impaired in tissues from alloxan-induced diabetic rats. Secondly, this increase in gliclazide bioavailability could also be the result of restoring the disturbed gut motility associated with diabetes [46] by probiotic treatment. Overall, the reason for the lower bioavailability of gliclazide in diabetic rats is unknown and awaits further research but one possible explanation is that changes in metabolic activation by the gut flora or in drug transporter activity and/or expression occur in diabetic animals.

In conclusion, T1D has been characterized mainly by glucose imbalance. Insulin has been the main stream treatment for T1D, but despite good control over blood glucose levels, T1D complications still occur. Accordingly, optimum control over blood glucose, maintaining tissues functionality and minimizing T1D complications can significantly optimize patient health status and well being. In recent years, probiotics and bile acids emerged as potential candidates that can be used as adjuvant agents to improve the treatment of diabetes.

## References

1. **Chao CC, Sytwu HK, Chen EL, Toma J, McDevitt HO** [1999] The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. *Proc Natl Acad Sci USA* 96: 9299-9304.
2. **Barbeau WE, Bassaganya-Riera J, Hontecillas R** [2007] Putting the pieces of the puzzle together - A series of hypotheses on the etiology and pathogenesis of type 1 diabetes. *Med Hypotheses* 68: 607-619.
3. **Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M** [2002] Environmental factors in the etiology of type 1 diabetes. *Am J Med Genet* 115: 18-29.
4. **Ghosh S, van Heel D, Playford RJ** [2004] Probiotics in inflammatory bowel disease: Is it all gut flora modulation? *Gut* 53: 620-622.
5. **Bourlioux P, Koletzko B, Guarner F, Braesco V** [2003] The intestine and its microflora are partners for the protection of the host: Report on the Danone Symposium "The Intelligent Intestine" (held in Paris, June 14, 2002). *Am J Clin Nutr* 78: 675-683.
6. **Houten S, Watanabe M, Auwerx J** [2006] Endocrine functions of bile acids. *EMBO J* 25: 1419-1425.
7. **Al-Salami H, Kansara H, King J, Morar B, Jayathilaka B, Fawcett PJ, et al.** [2007] Bile acids: A bitter sweet remedy for diabetes. *New Zealand Pharm J* 27: 17-20.
8. **Mikov M, Boni NS, Al-Salami H, Kuhajda K, Kevresan S, Golocorbin-Kon S, Fawcett JP** [2007] Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3 $\alpha$ ,7 $\alpha$ -dihydroxy-12-oxo-5 $\beta$ -cholanate, in healthy and diabetic rats. *Eur J Drug Metab Pharmacokinet* 32: 7-12.
9. **Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP** [2008] The influence of 3 $\alpha$ ,7 $\alpha$ -dihydroxy-12-keto-5 $\beta$ -cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. *Eur J Drug Metab Pharmacokinet* 33: 137-142.
10. **Rendall M** [2004] The role of sulphonylureas in the management of type 2 diabetes mellitus. *Drugs* 64: 1399-1358.
11. **Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI** [2004] Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. *Reprod Toxicol* 18: 619-621.
12. **Campbell DB, Lavielle R, Nathan C** [1991] The mode of action and clinical pharmacology of gliclazide: A review. *Diabetes Res Clin Pract* 14(Suppl 2): S21-S36.
13. **Smith RJ** [1990] Effects of the sulfonylureas on muscle glucose homeostasis. *Am J Med* 89: 38S-43S (discussion on 51S-53S).
14. **Jacobs DB, Hayes GR, Lockwood DH** [1989] In vitro effects of sulfonylurea on glucose transport and translocation of glucose transporters in adipocytes from streptozocin-induced diabetic rats. *Diabetes* 38: 205-211.
15. **Renier G, Desfaits AC, Serri O** [2000] Effect of gliclazide on monocyte-endothelium interactions in diabetes. *J Diabetes Complications* 14: 215-23.
16. **Palmer KJ, Brogden RN** [1993] Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. *Drugs* 46: 92-125.
17. **Stetinova V, Kvetina J, Pastera J, Polaskova A, Prazakova M** [2007] Gliclazide: Pharmacokinetic-pharmacodynamic relationships in rats. *Biopharm Drug Dispos* 28: 241-248.
18. **Al-Salami H, Grant Butt, Ian Tucker, Mikov M** [2008] Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. *Eur J Drug Metab Pharmacokinet* 33: 101-106.
19. **FAO/WHO** [2002] Guidelines for the evaluation of probiotics in food. In: Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food.
20. **Bezkorovainy A** [2001] Probiotics: Determinants of survival and growth in the gut. *Am J Clin Nutr* 73 (2 Suppl): 399S-405S.

21. **Karimi O, Pena AS** [2003] Probiotics: Isolated bacteria strain or mixtures of different strains? Two different approaches in the use of probiotics as therapeutics. *Drugs Today (Barc)* 39: 565-597.
22. **Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB, Ferretti E, Gulino A, Grasso F, De Simone C, Di Mario U, Falorni A, Boirivant M, Dotta F** [2005] Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. *Diabetologia* 48: 1565-1575.
23. **Rožanova GN, Voevodin DA, Stenina MA, Kushnareva MV** [2002] Pathogenetic role of dysbacteriosis in the development of complications of type 1 diabetes mellitus in children. *Bull Exp Biol Med* 133: 164-166.
24. **Bengmark S** [1998] Ecological control of the gastrointestinal tract. The role of probiotic flora. *Gut* 42: 2-7.
25. **Bomba A, Nemcova R, Mudronova D, Guba P** [2002] The possibilities of potentiating the efficacy of probiotics. *Trends Food Sci Technol* 13: 121-126.
26. **Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, et al.** [2005] Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. *Diabetologia* 48: 1565-1575.
27. **Chiang BL, Sheih YH, Wang LH, Liao CK, Gill HS** [2000] Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (*Bifidobacterium lactis* HN019): Optimization and definition of cellular immune responses. *Eur J Clin Nutr* 54: 849-855.
28. **Miljkovic D** [1996] Selective C-12 oxidation of cholic acid. *Chem Res* 2: 106-107.
29. **Carvalho Eliziane Nitz de, Carvalho Nestor Antônio Schmidt de, Ferreira Lydia Masako** [2003] Experimental model of induction of diabetes mellitus in rats. *Acta Cirurgica Brasileira* 18: 60-64.
30. **Korec R** [1980] Treatment of alloxan and streptozotocin diabetes in rats by intrafamilial homo (allo) transplantation of neonatal pancreases. *Endocrinol Exp* 14: 191-198.
31. **Bachmann K, Pardoe D, White D** [1996] Scaling basic toxicokinetic parameters from rat to man. *Environ Health Perspect* 104: 400-407.
32. **Alam MJ, Rahman MA** [1971] Changes in the saccharoid fraction in rats with alloxan-induced diabetes or injected with epinephrine. *Clin Chem* 17: 915-920.
33. **Khavinson VK** [2005] Effect of tetrapeptide on insulin biosynthesis in rats with alloxan-induced diabetes. *Bull Exp Biol Med* 140: 452-454.
34. **DeCarvalho I E, Carvalho II N, Ferreira L** [2003] Experimental model of induction of diabetes mellitus in rats. *Acta Cirurgica Brasileira* 18: 120-167.
35. **Park JY, Kim KA, Park PW, Park CW, Shin JG** [2003] Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. *Clin Pharmacol Ther* 74: 334-340.
36. **Rouini MR, Mohajer A, Tahami MH** [2003] A simple and sensitive HPLC method for determination of gliclazide in human serum. *J Chromatogr B Analyt Technol Biomed Life Sci* 785: 383-386.
37. (No Author listed) Win Nonlin program (version 1.1). 2005: Pharsight Corp. (Mountain View, CA).
38. **Al-Salami H, Butt G, Tucker I, Mikov M** [2008] The influence of probiotics pre-treatment on gliclazide pharmacokinetics and glucose levels in healthy and diabetic rats. *Eur J Drug Metab Pharmacokinet* (in press).
39. **Kuhajda K, Kevresan S, Kandrac J, Fawcett JP, Mikov M** [2006] Chemical and metabolic transformations of selected bile acids. *Eur J Drug Metab Pharmacokinet* 31: 179-235.
40. **Mikov M, Fawcett JP** [2006] Chemistry, biosynthesis, analysis, chemical and metabolic transformations and pharmacology. *Eur J Drug Metab Pharmacokinet* 31: 133-134.
41. **Bansil R, Stanley E, LaMont JT** [1995] Mucin biophysics. *Annu Rev Physiol* 57: 635-657.
42. **Garcia-Lafuente A, Antolin M, Guarner F, Crespo E, Malagelada JR** [2001] Modulation of colonic barrier function by the composition of the commensal flora in the rat. *Gut* 48: 503-507.
43. **Pigeon RM, Cuesta EP, Gililliand SE** [2002] Binding of free bile acids by cells of yogurt starter culture bacteria. *J Dairy Sci* 85: 2705-2710.
44. **Al-Salami H, Butt G, Tucker I, Mikov M** [2008] Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. *Pharmacol Reports* 60: 532-541.
45. **Al-Salami H, Butt G, Tucker I, Mikov M** [2008] Influence of the semisynthetic bile acid MKC on the Ileal Permeation of Gliclazide in vitro in Healthy and Diabetic Rats treated with Probiotics. *Methods Find Exp Clin Pharmacol* 30: 1-7.
46. **Iida M, Ikeda M, Kishimoto M, Tsujino T, Kaneto H, Matsuhisa M, et al.** [2000] Evaluation of gut motility in type II diabetes by the radiopaque marker method. *J Gastroenterol Hepatol* 15: 381-385.